Vibe Bio
resources
Case study: Orphan Therapeutics
How Orphan Therapeutics Accelerator is optimizing rare disease search & eval
Learn how Orphan Therapeutics Accelerator uses Vibe Bio for rare disease due diligence, pipeline and competitive analysis, and in-licensing strategy.
Webinar: Watch on-demand
The AI buying guide for BD&L executives
The AI buying guide for Business Development & Licensing (BD&L) executives Webinar on-demand Evaluate & choose AI solutions to achieve real results Your biopharma BD&L teams are under unprecedented pressure…
Additional resources
Scientific insights:The ActRIIB Challenge (LAE103)
The obesity market is undergoing a quiet revolution: it’s no longer about how much weight patients lose, but what kind of weight they lose.
Scientific insights: Urea cycle disorders
Drug hunters need to watch Urea Cycle Disorders! Gene therapies (cost) and ERTs (patient experience) still leave much to be desired.
Scientific insights: Kidney disease
Explore why kidney disease is emerging as a top therapeutic focus. See how VibeOne identifies high-potential kidney indications and guides strategic prioritization.
Biopharma BD&L: the tsunami is upon us
Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.
Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
Pharma portfolio analytics in a gen AI world
I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
No posts
Whitepaper: The AI buying guide for BD&L executives
AI is already transforming how leading organizations identify, evaluate, and close deals, but not all AI platforms are built for BD&L.
The Scoop – A conversation with Alok Tayi
“In this episode of The Scoop, Tayi shares his vision for how Vibe Bio aims to disrupt the centralized control of big pharma”
No posts
No posts
Uncover new possibilities with VibeOne
Learn how VibeOne can help you discover your next indication or identify high potential development opportunities in your portfolio.